RA Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

RA Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-280,000	Closed	-$14.9M	–	73
2015 Q2	$14.9M	Hold	280,000	–	–	1.5%	22
2015 Q1	$17M	Hold	280,000	–	–	1.69%	18
2014 Q4	$14.6M	Buy	+280,000	New	+$12.5M	1.57%	19

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GAMA

Graticule Asia Macro Advisors New York $649M AUM

RA Capital Management's JUNO Position: Q3 2015 in Review

RA Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2015, closing a stake of 280,000 shares — an estimated $14.9M sold.

RA Capital Management first reported a position in JUNO in Q4 2014 and held it in 3 quarters. The position peaked at $17M in Q1 2015. 132 funds tracked by Wall St. Rank hold JUNO as of Q3 2015.

RA Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
RA Capital Management sold 280,000 Juno Therapeutics, Inc. shares in Q3 2015, an estimated $14.9M.
RA Capital Management first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
RA Capital Management's Juno Therapeutics, Inc. position peaked at $17M in Q1 2015.
132 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2015.

Based on RA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.